Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts
Fulcrum Therapeutics (NASDAQ:FULC) has received a consensus "Reduce" recommendation from analysts, with an average 12-month price target of $8.20. Several firms recently downgraded the stock and set lower price targets. This comes as the company missed quarterly earnings expectations and its shares remain significantly …